Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
99% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ABMD' s Cash to Debt Range Over the Past 10 Years
Min: 31.75  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.88
ABMD's Equity to Asset is ranked higher than
90% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABMD: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
ABMD' s Equity to Asset Range Over the Past 10 Years
Min: 0.72  Med: 0.86 Max: 0.94
Current: 0.88
0.72
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
97% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. ABMD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ABMD' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 7
Z-Score: 52.84
M-Score: -1.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 19.02
ABMD's Operating margin (%) is ranked higher than
88% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. ABMD: 19.02 )
Ranked among companies with meaningful Operating margin (%) only.
ABMD' s Operating margin (%) Range Over the Past 10 Years
Min: -69.36  Med: -20.16 Max: 12.45
Current: 19.02
-69.36
12.45
Net-margin (%) 41.57
ABMD's Net-margin (%) is ranked higher than
99% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ABMD: 41.57 )
Ranked among companies with meaningful Net-margin (%) only.
ABMD' s Net-margin (%) Range Over the Past 10 Years
Min: -69.44  Med: -16.91 Max: 49.36
Current: 41.57
-69.44
49.36
ROE (%) 42.81
ABMD's ROE (%) is ranked higher than
98% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. ABMD: 42.81 )
Ranked among companies with meaningful ROE (%) only.
ABMD' s ROE (%) Range Over the Past 10 Years
Min: -46.87  Med: -14.02 Max: 49.44
Current: 42.81
-46.87
49.44
ROA (%) 37.15
ABMD's ROA (%) is ranked higher than
98% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. ABMD: 37.15 )
Ranked among companies with meaningful ROA (%) only.
ABMD' s ROA (%) Range Over the Past 10 Years
Min: -42.19  Med: -11.67 Max: 41.81
Current: 37.15
-42.19
41.81
ROC (Joel Greenblatt) (%) 105.13
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. ABMD: 105.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -259.63  Med: -121.12 Max: 90.23
Current: 105.13
-259.63
90.23
Revenue Growth (3Y)(%) 19.50
ABMD's Revenue Growth (3Y)(%) is ranked higher than
89% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ABMD: 19.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABMD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.2  Med: 10.80 Max: 19.5
Current: 19.5
-7.2
19.5
EBITDA Growth (3Y)(%) 69.50
ABMD's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. ABMD: 69.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: 11.45 Max: 133.8
Current: 69.5
-56.2
133.8
EPS Growth (3Y)(%) 315.40
ABMD's EPS Growth (3Y)(%) is ranked higher than
98% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABMD: 315.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.8  Med: 11.60 Max: 315.4
Current: 315.4
-52.8
315.4
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ABMD Guru Trades in Q4 2014

Joel Greenblatt 22,440 sh (New)
PRIMECAP Management 5,687,590 sh (+0.40%)
Chase Coleman Sold Out
» More
Q1 2015

ABMD Guru Trades in Q1 2015

Jim Simons 188,263 sh (New)
Paul Tudor Jones 12,243 sh (New)
Joel Greenblatt 22,429 sh (-0.05%)
PRIMECAP Management 5,662,590 sh (-0.44%)
» More
Q2 2015

ABMD Guru Trades in Q2 2015

Steven Cohen 105,000 sh (New)
Joel Greenblatt 67,429 sh (+200.63%)
Jim Simons 450,473 sh (+139.28%)
Paul Tudor Jones 14,516 sh (+18.57%)
PRIMECAP Management 5,668,090 sh (+0.10%)
» More
Q3 2015

ABMD Guru Trades in Q3 2015

PRIMECAP Management 5,668,090 sh (unchged)
Steven Cohen Sold Out
Jim Simons 363,723 sh (-19.26%)
Paul Tudor Jones 8,813 sh (-39.29%)
Joel Greenblatt 15,078 sh (-77.64%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.35
ABMD's P/E(ttm) is ranked lower than
52% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 26.20 vs. ABMD: 24.35 )
Ranked among companies with meaningful P/E(ttm) only.
ABMD' s P/E(ttm) Range Over the Past 10 Years
Min: 22.59  Med: 88.57 Max: 946.92
Current: 24.35
22.59
946.92
Forward P/E 70.42
ABMD's Forward P/E is ranked lower than
90% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. ABMD: 70.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.35
ABMD's PE(NRI) is ranked lower than
52% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 25.70 vs. ABMD: 24.35 )
Ranked among companies with meaningful PE(NRI) only.
ABMD' s PE(NRI) Range Over the Past 10 Years
Min: 22.57  Med: 89.60 Max: 820.67
Current: 24.35
22.57
820.67
P/B 8.67
ABMD's P/B is ranked lower than
92% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. ABMD: 8.67 )
Ranked among companies with meaningful P/B only.
ABMD' s P/B Range Over the Past 10 Years
Min: 1.58  Med: 5.01 Max: 14.18
Current: 8.67
1.58
14.18
P/S 11.17
ABMD's P/S is ranked lower than
88% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ABMD: 11.17 )
Ranked among companies with meaningful P/S only.
ABMD' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 6.11 Max: 17.76
Current: 11.17
2.38
17.76
PFCF 56.96
ABMD's PFCF is ranked lower than
87% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 56.96 )
Ranked among companies with meaningful PFCF only.
ABMD' s PFCF Range Over the Past 10 Years
Min: 15.99  Med: 47.78 Max: 2462
Current: 56.96
15.99
2462
POCF 50.10
ABMD's POCF is ranked lower than
87% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 50.10 )
Ranked among companies with meaningful POCF only.
ABMD' s POCF Range Over the Past 10 Years
Min: 14.41  Med: 47.21 Max: 463.25
Current: 50.1
14.41
463.25
EV-to-EBIT 52.36
ABMD's EV-to-EBIT is ranked lower than
86% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.49 vs. ABMD: 52.36 )
Ranked among companies with meaningful EV-to-EBIT only.
ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -305.5  Med: -9.60 Max: 694.7
Current: 52.36
-305.5
694.7
EV-to-EBITDA 49.68
ABMD's EV-to-EBITDA is ranked lower than
89% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. ABMD: 49.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.6  Med: -10.80 Max: 727.3
Current: 49.68
-397.6
727.3
Current Ratio 7.70
ABMD's Current Ratio is ranked higher than
88% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. ABMD: 7.70 )
Ranked among companies with meaningful Current Ratio only.
ABMD' s Current Ratio Range Over the Past 10 Years
Min: 3.18  Med: 6.62 Max: 15.95
Current: 7.7
3.18
15.95
Quick Ratio 7.04
ABMD's Quick Ratio is ranked higher than
89% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABMD: 7.04 )
Ranked among companies with meaningful Quick Ratio only.
ABMD' s Quick Ratio Range Over the Past 10 Years
Min: 2.56  Med: 5.56 Max: 15.43
Current: 7.04
2.56
15.43
Days Inventory 159.94
ABMD's Days Inventory is ranked lower than
57% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. ABMD: 159.94 )
Ranked among companies with meaningful Days Inventory only.
ABMD' s Days Inventory Range Over the Past 10 Years
Min: 136.58  Med: 145.90 Max: 314.91
Current: 159.94
136.58
314.91
Days Sales Outstanding 44.36
ABMD's Days Sales Outstanding is ranked higher than
82% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. ABMD: 44.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.41  Med: 58.33 Max: 87.14
Current: 44.36
48.41
87.14
Days Payable 69.27
ABMD's Days Payable is ranked higher than
55% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. ABMD: 69.27 )
Ranked among companies with meaningful Days Payable only.
ABMD' s Days Payable Range Over the Past 10 Years
Min: 60.98  Med: 97.51 Max: 218.64
Current: 69.27
60.98
218.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.96
ABMD's Price/Net Cash is ranked lower than
75% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 12.77 vs. ABMD: 25.96 )
Ranked among companies with meaningful Price/Net Cash only.
ABMD' s Price/Net Cash Range Over the Past 10 Years
Min: 1.29  Med: 10.52 Max: 73.96
Current: 25.96
1.29
73.96
Price/Net Current Asset Value 15.50
ABMD's Price/Net Current Asset Value is ranked lower than
78% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. ABMD: 15.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ABMD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.08  Med: 6.41 Max: 22.32
Current: 15.5
1.08
22.32
Price/Tangible Book 11.56
ABMD's Price/Tangible Book is ranked lower than
87% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 3.79 vs. ABMD: 11.56 )
Ranked among companies with meaningful Price/Tangible Book only.
ABMD' s Price/Tangible Book Range Over the Past 10 Years
Min: 1  Med: 5.74 Max: 17.13
Current: 11.56
1
17.13
Price/Projected FCF 6.35
ABMD's Price/Projected FCF is ranked lower than
84% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. ABMD: 6.35 )
Ranked among companies with meaningful Price/Projected FCF only.
ABMD' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.73  Med: 7.10 Max: 36.63
Current: 6.35
3.73
36.63
Price/Median PS Value 2.11
ABMD's Price/Median PS Value is ranked lower than
89% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. ABMD: 2.11 )
Ranked among companies with meaningful Price/Median PS Value only.
ABMD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 0.99 Max: 4.29
Current: 2.11
0.38
4.29
Price/Graham Number 3.90
ABMD's Price/Graham Number is ranked lower than
76% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. ABMD: 3.90 )
Ranked among companies with meaningful Price/Graham Number only.
ABMD' s Price/Graham Number Range Over the Past 10 Years
Min: 3.03  Med: 5.53 Max: 17.9
Current: 3.9
3.03
17.9
Earnings Yield (Greenblatt) (%) 1.86
ABMD's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. ABMD: 1.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.10 Max: 3.7
Current: 1.86
0.1
3.7

More Statistics

Revenue(Mil) $303
EPS $ 2.83
Beta-0.30
Short Percentage of Float5.85%
52-Week Range $54.20 - 110.68
Shares Outstanding(Mil)42.42

Analyst Estimate

Mar16 Mar17 Mar18
Revenue(Mil) 313 431 596
EPS($) 0.60 1.10 1.86
EPS without NRI($) 0.60 1.10 1.86

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany,
Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Panic-Proofing the Small Investor Aug 26 2015 
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 

More From Other Websites
Iradimed (IRMD) Q4 Earnings in Line: Revenues Up Y/Y Feb 08 2016
Abiomed Outshines Q3 Earnings & Revenues, FY16 View Up Feb 08 2016
Abiomed Announces Appointments of Jeannine Rivet and Christopher Van Gorder to Board of Directors Feb 08 2016
ABIOMED INC Files SEC form 10-Q, Quarterly Report Feb 05 2016
Zacks Investment Ideas feature highlights: True Blue, Boston Properties, Fabrinet and Abiomed Feb 05 2016
ABIOMED (ABMD) Looks Good: Stock Adds 8.5% in Session Feb 05 2016
Edited Transcript of ABMD earnings conference call or presentation 4-Feb-16 1:00pm GMT Feb 04 2016
Abiomed, Boston Scientific Move Opposite Ways On Quarterly Reports Feb 04 2016
Abiomed beats 3Q profit forecasts Feb 04 2016
Abiomed beats 3Q profit forecasts Feb 04 2016
Abiomed's Stock Gains Following Positive Q3, Revised Guidance Feb 04 2016
Abiomed Inc Earnings Call scheduled for 8:00 am ET today Feb 04 2016
ABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 04 2016
Q3 2016 Abiomed Inc Earnings Release - Before Market Open Feb 04 2016
Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year Feb 04 2016
Why ABIOMED (ABMD) Might Surprise This Earnings Season Feb 03 2016
ABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : February 1, 2016 Feb 01 2016
Zacks Investment Ideas feature highlights: Intuitive Surgical, Abiomed, Exactech and Iradimed Jan 26 2016
Abiomed Third Quarter Fiscal 2016 Earnings and Conference Call Notification Jan 26 2016
Abiomed Third Quarter Fiscal 2016 Earnings and Conference Call Notification Jan 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK